AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17485570
Drug: Metformin 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1,000 mg (M1000)
Trial: 17485570
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg (S100)
Trial: 17485570
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg/metformin 2,000 mg (S100/M2000) in open-label cohort
Trial: 17485570
Drug: Co-administration therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration therapies vs respective metformin monotherapy
Trial: 10102256
Drug: Sibutramine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 30 mg/day
Trial: 7993330
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment (stimulus control, urge control, contracting/family support, competing response procedures) for an average of 19 sessions
Trial: 7993330
Drug: Supportive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive treatment (alternative treatment)
Trial: 2951426
Drug: Ordinary dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary dosage of ipratropium (80 micrograms four times a day)
Trial: 2951426
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy of ipratropium (400 micrograms four times a day)
Trial: 25355680
Drug: Adjuvant procarbazine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant procarbazine, CCNU, and vincristine (PCV) chemotherapy after 54 Gy of radiotherapy (RT)
Trial: 23193678
Drug: Qianlieping Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianlieping Capsule plus tamsulosin
Trial: 23193678
Drug: Qianlieping Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianlieping Capsule alone
Trial: 15223898
Drug: Two-dose basiliximab
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Two-dose basiliximab with low initial CsA triple therapy (group B)
Trial: 15223898
Drug: Conventional triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional triple therapy (group C)
Trial: 11725330
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (20 g/d for 6 days, then 6 g/d for 4 weeks)
Trial: 8215564
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage surfactant regimen (100 mg/kg initially, with two further doses at 12 and 24 hours to a maximum cumulative total of 300 mg/kg; n = 1069)
Trial: 8215564
Drug: High dosage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosage surfactant regimen (200 mg/kg initially with up to four further doses of 100 mg/kg to a maximum cumulative total of 600 mg/kg; n = 1099)
Trial: 8215564
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage surfactant regimen
Trial: 8215564
Drug: High dosage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosage surfactant regimen
Trial: 31515428
Drug: Methotrimeprazine 6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrimeprazine 6.25 mg
Trial: 31515428
Drug: Haloperidol 1.5
RxNorm normalized name: haloperidol 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 1.5 mg
Trial: 26975312
Drug: Transregional interferential
RxNorm normalized name: thymol
DrugBank: Thymol (DB02513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transregional interferential current therapy (10 sessions of 25 minutes over two weeks)
Trial: 24273182
Drug: CVD 908-htrA
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 908-htrA vaccine in H. pylori infected subjects
Trial: 24273182
Drug: CVD 908-htrA
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 908-htrA vaccine in subjects with low PG I:PG II ratio (<5)
Trial: 24273182
Drug: CVD 908-htrA
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 908-htrA vaccine in H. pylori uninfected subjects
Trial: 24273182
Drug: CVD 908-htrA
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 908-htrA vaccine with Hepatitis A infection
Trial: 22938439
Drug: Continuous transarterial
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transarterial infusion chemotherapy with gemcitabine (1000 mg/m2) and 5-Fluorouracil (600 mg/m2)
Trial: 22938439
Drug: Systemic venous
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic venous chemotherapy with gemcitabine (1000 mg/m2) and 5-Fluorouracil (600 mg/m2)
Trial: 15205720
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ALN
Trial: 15205720
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ALN
Trial: 15205720
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ALN
Trial: 3305850
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and diuretics
Trial: 3305850
Drug: Theophylline and
RxNorm normalized name: theophylline and adrenergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline and diuretics
Trial: 18270772
Drug: Conventional laparoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional laparoscopic tumor-specific mesorectal excision (L-TSME)
Trial: 15745109
Drug: Beta-blockers (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (group B; n = 15)
Trial: 7750282
Drug: Nestorone subdermal
RxNorm normalized name: Nestorone
DrugBank: Segesterone acetate (DB14583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nestorone subdermal implant (Implant A)
Trial: 7750282
Drug: Nestorone subdermal
RxNorm normalized name: Nestorone
DrugBank: Segesterone acetate (DB14583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nestorone subdermal implant (Implant B)
Trial: 7750282
Drug: Nestorone subdermal
RxNorm normalized name: Nestorone
DrugBank: Segesterone acetate (DB14583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nestorone subdermal implant
Trial: 7350294
Drug: Human growth
RxNorm normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human growth hormone (hGH)
Trial: 7350294
Drug: Oxandrolone +
RxNorm normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxandrolone + Human growth hormone (Ox + hGH)
Trial: 28638060
Drug: Epidural group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural group (Group E): TEA with levobupivacaine and dexmedetomidine, intravenous saline infusion
Trial: 28638060
Drug: Intravenous group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous group (Group V): TEA with levobupivacaine, intravenous dexmedetomidine infusion
Trial: 28638060
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group C): TEA with levobupivacaine alone, intravenous saline infusion
Trial: 25854859
Drug: Pradigastat (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradigastat (1, 3, 10, 30, 100, or 300 mg)
Trial: 25854859
Drug: Pradigastat (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradigastat (1, 5, 10, or 25 mg)
Trial: 25854859
Drug: Pradigastat (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradigastat (single and multiple doses)
Trial: 24088535
Drug: Mindfulness Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness Based Stress Reduction (MBSR) Intervention I (weekly group sessions + self‐instructing program)
Trial: 21843685
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg orally and misoprostol 800 mcg vaginally
Trial: 17920976
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl (INF) 180 mug +/‐ 2 doses of 60 mug at > or =5‐minute intervals
Trial: 17920976
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (IVM) 2.5 to 5 mg +/‐ 2 doses of 2.5 to 5 mg at > or =5‐minute intervals
Trial: 8698737
Drug: Dexverapamil plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexverapamil plus chemotherapy (vindesine/etoposide)
Trial: 8698737
Drug: Chemotherapy (vindesine/etoposide)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (vindesine/etoposide) alone
Trial: 302111
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of vasopressin via peripheral vein
Trial: 302111
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of vasopressin via superior mesenteric artery (SMA)
Trial: 29627898
Drug: SSRI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI treatment with paroxetine for 8 weeks
Trial: 9491842
Drug: Vancomycin therapy
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin therapy
Trial: 8726538
Drug: Intranasal apomorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal apomorphine monotherapy
Trial: 9756146
Drug: Intranasal apomorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal apomorphine
Trial: 8726538
Drug: Intranasal apomorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal apomorphine with trimethobenzamide
Trial: 1756271
Drug: melphalan (L-PAM)
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: melphalan (L-PAM)
Trial: 1756271
Drug: post-operative radiation
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: post-operative radiation therapy (RT)
Trial: 7169959
Drug: Oestradiol diether
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestradiol diether (promestriene) administered via gynaecological capsules for 40 consecutive days
Trial: 7169959
Drug: Excipient (control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excipient (control) administered via gynaecological capsules for 40 consecutive days
Trial: 11180035
Drug: Oral tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tacrolimus (5 mg)
Trial: 17122448
Drug: Dual ET-receptor
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual ET-receptor blockade in controls
Trial: 17122448
Drug: Dual ET-receptor
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual ET-receptor blockade in SCI
Trial: 17122448
Drug: Selective ET(A)-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective ET(A)-receptor blockade in SCI
Trial: 8555852
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT) - 16 individual weekly sessions in addition to medical care
Trial: 1810080
Drug: Pamidronate 75
RxNorm normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate 75 mg daily
Trial: 9797692
Drug: Pamidronate 150
RxNorm normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate 150 mg daily
Trial: 30528802
Drug: Weekly paclitaxel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly paclitaxel, liposomal doxorubicin (plus carboplatin in TNBC) (PM(Cb))
Trial: 28198120
Drug: Lecithinized curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecithinized curcumin (1 g/day for 6 weeks)
Trial: 28198120
Drug: Unformulated curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unformulated curcumin (1 g/day for 6 weeks)
Trial: 23078651
Drug: Pimobendan (Vetmedin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimobendan (Vetmedin capsules)
Trial: 19177449
Drug: Standard-dose tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose tacrolimus (10-15 ng/mL) plus intravenous MMF (1 g twice daily) with corticosteroids
Trial: 19177449
Drug: Reduced-dose tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose tacrolimus (5-8 ng/mL) plus intravenous MMF (1 g twice daily) with corticosteroids
Trial: 17150015
Drug: Gene and
RxNorm normalized name: lipid nanoparticle encapsulating single guide RNA (G012267) targeting the human KLKB1 gene and messenger RNA (mRNA000042) encoding Cas9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene and cell therapies for myocardial neovascularisation
Trial: 10504080
Drug: Alcohol epithelial
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol epithelial removal (20% ethanol solution applied for 20 seconds)
Trial: 8695463
Drug: Assessment and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment and treatment in primary care using a trained nurse
Trial: 1654136
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam (four consecutive, logarithmically increasing doses)
Trial: 27920497
Drug: CKD‐828 2.5/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD‐828 2.5/40 mg
Trial: 27920497
Drug: CKD‐828 2.5/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD‐828 2.5/80 mg
Trial: 27920497
Drug: S‐amlodipine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐amlodipine 2.5 mg
Trial: 12669122
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily subcutaneous LMWH (bemiparin) for one week (group B)
Trial: 12669122
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily bemiparin in a therapeutic dose for one week followed by a maintenance dose for 12 weeks (group C)
Trial: 3972652
Drug: Benznidazole (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benznidazole (up to 40 mg/kg)
Trial: 3972652
Drug: CCNU (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCNU (130 mg/m2)
Trial: 30858208
Drug: Omadacycline 200
RxNorm normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omadacycline 200 mg i.v. on day 1, then 300 mg orally q24h
Trial: 30858208
Drug: Omadacycline 300
RxNorm normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omadacycline 300 mg orally q12h on day 1, then 300 mg orally q24h
Trial: 30858208
Drug: Omadacycline 450
RxNorm normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omadacycline 450 mg orally q12h on day 1, then 450 mg orally q24h
Trial: 22340605
Drug: Optical Path
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Optical Path Difference Custom Aspheric Treatment (OPDCAT)
Trial: 17572410
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg daily for 6 months
Trial: 15969897
Drug: Montelukast 4‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 4‐mg oral granules
Trial: 8572359
Drug: Epidural catheters
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural catheters resulting in intravenous cannulation
Trial: 8383088
Drug: No antitumor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antitumor therapy (n = 36)
Trial: 29489046
Drug: Prazosin (alpha-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (alpha-adrenergic agonist)
Trial: 27439724
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health promotion intervention (INT) delivered by trained Navajo lay health workers, including 5 interactions for children, 4 for parents, and 4 fluoride varnish applications over 3 years.
Trial: 27439724
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health promotion intervention (INT)
Trial: 27439724
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health promotion intervention (INT) among adherent children
Trial: 21674393
Drug: Robot-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted therapy using MIME (high-dose, 30 hours)
Trial: 21674393
Drug: Robot-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted therapy using MIME (low-dose, 15 hours)
Trial: 21674393
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional therapy, up to 15 hours)
Trial: 18680490
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 110 microg once daily
Trial: 18680490
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 55 microg once daily
Trial: 2554244
Drug: Oral rhesus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rhesus rotavirus vaccine (RRV) with oral poliovirus vaccine (OPV)
Trial: 2554244
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with oral poliovirus vaccine (OPV)
Trial: 2554244
Drug: Oral rhesus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rhesus rotavirus vaccine (RRV) 2 weeks after OPV
Trial: 28878181
Drug: DHA (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (200 mg/day) and ARA (200 mg/day) supplement
Trial: 523503
Drug: Furosemide (oral)
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide (oral)
Trial: 27530232
Drug: Furosemide (intravenous)
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide (intravenous)
Trial: 24960147
Drug: etoricoxib 120
RxNorm normalized name: etoricoxib 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 120 mg qd
Trial: 9035016
Drug: ibuprofen 600
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen 600 mg qid
Trial: 21544882
Drug: Salvia miltiorrhiza
RxNorm normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvia miltiorrhiza hydrophilic extract (SMHE) plus hypoglycemic therapy
Trial: 21544882
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus hypoglycemic therapy
Trial: 17601439
Drug: Misted administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misted administration of tropicamide 1.0% (6 microl)
Trial: 17601439
Drug: Conventional drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drop administration of tropicamide 1.0% (30 microl)
Trial: 15177812
Drug: Treatment-refractory patients
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-refractory patients with schizophrenia
Trial: 12408210
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (for smokers ready to quit)
Trial: 9583345
Drug: Brief treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief treatment of depression (16-week duration)
Trial: 9583345
Drug: Independent assessments
RxNorm normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Independent assessments during treatment
Trial: 7661573
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tropisetron capsule
Trial: 2589659
Drug: Oral cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporine (CYS) given 4 to 7 hours preoperatively